Tissuecypher® outperforms pathologist diagnoses when predicting progression in patients diagnosed with barrett's esophagus with low-grade dysplasia

Friendswood, texas--(business wire)---- $cstl #barretsesophagus--castle announced new data showing that its tissuecypher® test outperformed standard of care in predicting progression in barrett's esophagus patients.

CSTL Ratings Summary

CSTL Quant Ranking